This multicentre, prospective study evaluated the efficacy and safety of 7-day oral moxifloxacin (400 mg/day) for treatment of acute maxillary sinusitis after first-line treatment failure (group 1), and acute sinusitis with high risk of complications (group 2). Two hundred and fifty-eight patients with radiologically confirmed acute sinusitis were enrolled by 52 investigators; 216 patients (83.7%) qualified for per protocol efficacy analysis (group 1, n = 175; group 2, n = 41), and 92 for bacteriological analysis. Samples were collected from the middle meatus. The clinical success rate 7 -10 days posttreatment was 92.6%. Bacteriological success rates were 95.7% after 3 -4 days of treatment, and 97.2% and 95.2%, in group 1 and group 2, respectively, at 7 -10 days post-treatment. Drug-related adverse events, including abdominal pain (2.4%), nausea (2.4%) and diarrhoea (1.2%), were reported in 12.2% of patients. Overall, moxifloxacin therapy resulted in rapid bacteriological eradication, with a high rate of clinical success.
Moxifloxacin in the Treatment of Acute
Maxillary Sinusitis after First-line Treatment Failure and Acute Sinusitis with High Risk of Complications* Introduction Acute sinusitis is common in community practice, and primarily affects the maxillary sinuses. Initial symptoms often appear to be viral, but bacterial superinfection also occurs, 1 and requires a course of antimicrobial therapy, usually empirical. Empirical antimicrobial therapy is directed against the most commonly encountered bacterial pathogens to avoid the potential risk of serious complications, especially orbital or meningoencephalitic infections, which may not always be clinically identified at onset. The spectrum of the antibiotic used should include Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Other bacterial pathogens, such as Staphylococcus aureus, Enterobacteriaceae and anaerobic bacteria, 2 -4 are isolated with variable frequency; the latter being most often isolated from subacute or chronic forms of the disease. 5, 6 Recent national and international surveillance studies have shown an increase in isolation frequency of β-lactamase producing strains, with rates higher than 30% for H. influenzae 7, 8 and about 90% for M. catarrhalis. 8, 9 Similarly, decreased susceptibility of pneumococcal strains to penicillin G (minimal inhibitory concentrations [MIC] ≥ 0.125 mg/l) is generally observed, with isolation rates of strains with intermediate susceptibility or resistance reaching nearly 40%. 10 -12 The French marketing authorization agency, the Autorisation de Mise sur le Marché (AMM), has labelled a large number of antibiotics as indicated for sinusitis. Epidemiology and the evolution of resistance to antibiotics, however, have limited this label to just a few antibiotics, including amoxicillin clavulanate, second or third generation oral cephalosporins and pristinamycin, especially in cases of allergy to β-lactams. The first-line empirical treatment of acute maxillary sinusitis therefore presents no special problem. 13 The prescription of fluoroquinolones may not be justified as first-line treatment of maxillary sinusitis, but their tissue diffusion capacity, pharmacodynamic properties and antimicrobial activity against S. pneumoniae may be highly valuable for treating frontal or sphenoidal sinuses, or maxillary sinusitis after failure of empirical antimicrobial therapy.
Moxifloxacin has proven efficacious in the first-line treatment of acute sinusitis, most often in infections localized to the maxillary area. 14, 15 We have, therefore, evaluated the efficacy of moxifloxacin for treating acute maxillary sinusitis after confirmed failure of empirical antimicrobial therapy and acute sinusitis with a higher risk of complications, such as frontal or sphenoidal sinusitis and pansinusitis.
Patients and methods
Between January 2001 and July 2001, 52 community ear, nose and throat practitioners throughout France conducted this multicentre, non-comparative clinical study, which was co-ordinated by one of the authors. The French Human Investigations Committee, the Comité de Protection des Personnes se Prêtant à la Recherche Biomédicale (CCPPRB) of Paris-Necker approved the protocol on 16 November 2000.
PATIENTS
Eligible patients were men and women ≥ 18 years of age, with suspected acute bacterial sinusitis and evidence of purulent rhinorrhoea confirmed by nasal endoscopy. Symptoms included nasal congestion and at least one of the following: spontaneous/ induced infra-orbital pain, frontal cephalalgia, cough or frequent throatclearing, and temperature ≥ 38.0 ºC. Radiological and/or tomodensitometric tests were conducted within 48 h prior to treatment initiation and were evaluated by the study co-ordinator (centralized review). Acute sinusitis was confirmed if radiographs showed mucosal thickening of ≥ 6 mm and/or sinus opacity, and/or intra-sinus fluid. For patients presenting with maxillary sinusitis, first-line therapy failure was defined as persistence of symptoms after administration of a systemic antimicrobial (not a fluoroquinolone) course of therapy for at least 72 h. Prospective participants were required to provide written informed consent prior to enrolment in the study.
Exclusion criteria were: suspected bacteraemia or meningitis; history of sinus surgery; chronic sinusitis; > 2 episodes of sinusitis within the past 6 months; immunosuppression (neutropaenia, documented HIV infection); need for concomitant systemic antimicrobial therapy; pregnancy or breast feeding; documented hypersensitivity to moxifloxacin, its excipients or other quinolones; renal impairment (baseline serum creatinine > 265 µmol/l); severe hepatic impairment or increased transaminase rate (× 5 the upper limit of normal); congenital or acquired prolonged QT intervals; hydroelectrolytic disorders; uncorrected hypokalaemia; clinically significant bradycardia, especially cardiac insufficiency through reduction of the left ventricular ejection fraction; previous history of clinically significant arrhythmia; and/or co-administration of other medications reported to prolong QT intervals.
TREATMENT
All patients were treated with 400 mg/day of moxifloxacin orally for 7 days. Patients were instructed to take each dose at the same time every day, regardless of mealtime. Concomitant medications not permitted included all formulations of corticosteroids and systemic or locally administered antibiotics other than the study drug, except in cases of treatment failure or study termination. Other concomitant prescribed medications were permitted and were required to be reported.
STUDY DESIGN
Each investigator collected a medical history, performed a radiological assessment and complete physical examination, verified each patient's eligibility, and obtained a signed consent form at the inclusion consultation visit (V1). Two swab specimens of sinus secretions were collected from the middle meatus. If sphenoidal sinusitis was suspected, the swab specimen was collected from the posterior pharynx wall.
A second consultation (V2) on day 3 or day 4 of treatment was conducted to evaluate clinical progress, tolerance and treatment compliance, and to collect a new swab specimen for bacteriological testing.
During a third visit (V3) between day 7 and day 10 post-treatment, a physical examination was performed and a new swab specimen collected if pus was still present. Patients with a clinical cure at V3 were contacted by telephone 4 -5 weeks post-treatment, to document lack of clinical relapse.
BACTERIOLOGICAL PROTOCOL
One of the swab specimens collected at V1 was examined directly. The other was cultured in Portagerm ® agar (bioMérieux, Marcy l'Etoile, France) and sent to the microbiology laboratory at the Necker-Enfants Malades hospital via courier or Chronopost (arriving within 1 -3 days).
Swabs were cultured in agar containing 5% equine blood, chocolate-polyvitex agar, and polyvitex VCAT (bioMérieux) agar and incubated under 10% CO 2 at 37 ºC for 48 h. In addition, a blood agar was incubated in anaerobic conditions at 37 ºC for 48 h. Each bacterial pathogen was identified, and β-lactamase susceptibility was determined by a nitrocefin test (Cefinase O, bioMérieux). Following a bacterial count, a complete antibiogram was conducted, including an oxacillin disk test (5 µg dose) for detection of pneumococcal strains with abnormal/reduced susceptibility to penicillin (PSAP). MICs of S. pneumoniae and H. influenzae strains were determined by dilution in Mueller-Hinton agar supplemented by 5% fresh equine blood (Eurobio Laboratories, Les Ulis, France) for S. pneumoniae, or Fildès extracts (Oxoid, Hampshire, UK) for H. influenzae strains. PSAP was defined as an MIC range between 0.1 mg/l and 1 mg/l for penicillin G, and penicillinresistant S. pneumoniae (PRSP) was defined as an MIC > 1 mg/l for penicillin G. Moxifloxacin and acute maxillary sinusitis
EFFICACY EVALUATION
The primary efficacy variable was clinical response at 7 -10 days post-treatment (V3). Clinical success was defined as the complete resolution of all clinical signs and symptoms of sinusitis, and failure as persistence or worsening of symptoms.
Secondary efficacy variables were clinical and bacteriological response on days 3 -4 of treatment (V2) and the follow-up telephone interview (4 -5 weeks post-treatment), and bacteriological response at V3. A bacteriological response at V2, especially documentation of bacteriological eradication, was considered the most important response criteria. Clinical response is the major efficacy evaluation criterion for this type of infection, and we did not believe it was necessary, due to lack of correlation between improvement of radiological symptoms and clinical success, to obtain a control radiograph after treatment.
Two populations were defined for the efficacy analysis: i) The intent-to-treat (ITT) population included all patients who received at least one dose of study medication. Safety analysis was conducted on this population; ii) The 'qualified' per protocol (PP) population included all patients who were eligible for ITT, had a clinically and radiologically confirmed diagnosis of acute sinusitis, were treated for ≥ 5 days (or ≥ 3 days, in the case of early failure), did not take concomitant treatments and had a clinical assessment at V3 (for patients classified as treatment success).
SAFETY EVALUATION
Safety evaluation was based on reported adverse events observed after administration of the first dose of study medication until 7 -10 days following administration of the last dose. Adverse events were recorded according to their importance, severity, duration and possible or probable relationship with the study medication. Serious adverse events were followed up until the end of the study, i.e. 4 -5 weeks after the administration of the last dose.
STATISTICAL ANALYSIS
Demographic parameters, disease characteristics, efficacy parameters and adverse events were analysed with descriptive statistics. Quantitative data were described as mean, standard deviation, median, quartiles and minimum/maximum, whereas qualitative or categorical data were described by incidence.
Results

STUDY POPULATION
Two hundred and fifty-eight patients were enrolled in the study. Three patients did not receive study medication, so 255 were included in the ITT population. Thirty-nine patients were excluded from the PP analysis for the following reasons: violation of inclusion/exclusion criteria, most frequently due to radiographs not supporting the diagnosis (18 patients); schedule violations of V3 (14 patients); and lack of clinical evaluation or an 'indeterminate' evaluation at V3 (seven patients). The PP population therefore comprised 216 patients (83.7%), 41 of whom had sinusitis with high risk of complications and 175 who had maxillary sinusitis after first-line treatment failure. Baseline demographic and sinusitis characteristics of the PP population are summarized in Table 1 . The mean temperature was 37.5 ºC and 57/216 patients (26.4%) had a temperature ≥ 38.0 ºC. Common symptoms included anterior and/or posterior purulent rhinorrhoea and pain, characterized as either infra-orbital (~80%) or sub-orbital cephalalgia (> 60%).
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Prior antimicrobial therapy had been administered to 187 patients (86.6%) in the PP population ( Table 2 ). The most commonly prescribed antibiotics were amino-penicillins, usually administered at their recommended doses. The mean duration of prior antimicrobial therapy (7.2 days) was considerably longer than that required by the protocol to be defined as first-line treatment failure.
BACTERIOLOGICAL DOCUMENTATION
Swab specimens were collected from sinus secretions of all patients in the PP population, and 102 bacterial pathogenic strains were isolated from 92 of the 216 patients (42.6%). The rate of bacteriological documentation was slightly higher in patients with sinusitis with risk of complications (21/41 patients [51.2%]), than in patients with maxillary sinusitis after first-line treatment failure (71/175 [40.6%]). The majority of swab specimens were monomicrobial; two different bacteria were observed in only 10/92 patients. The bacterial strains isolated are summarized in Table 3 . Among the pneumococcal strains, decreased susceptibility to penicillin G was observed in 14 of 30 strains (46.7%), and a high level of resistance (MIC > 1 mg/l) was Moxifloxacin MIC values for isolated bacterial strains were consistently < 2 mg/l. MIC values ranging from 1 -2 mg/l were observed in only three strains: two strains of oxacillin-resistant S. aureus and one strain of Pseudomonas aeruginosa.
TREATMENT COMPLIANCE
Mean moxifloxacin treatment duration was 7.0 ± 0.3 days. All patients included in the PP population were treated for at least 5 days, and a full course of treatment was administered to 211 patients (97.7%).
CLINICAL EFFICACY
Clinical responses were recorded on days 3 -4 of treatment (V2), days 7 -10 post-treatment 
BACTERIOLOGICAL EFFICACY
Bacterial eradication at V2 was observed in 88 of the 92 PP patients (95.7%; documented, n = 74; assumed, n = 14) who had a bacterial infection at study enrolment. The four persistent cases involved two pneumococcal strains (one with decreased susceptibility to penicillin G), one β-lactamase-producing H. influenzae strain, and one P. aeruginosa strain. At V3, bacteriological success (documented/ assumed eradication) was confirmed in 97.2% (69/71) of patients with maxillary sinusitis after first-line treatment failure and 95.2% (20/21) of patients with sinusitis and risk of complications. Bacteriological failures (persistence) included two patients in the first group (with non-β-lactamase-producing H. influenzae and oxacillin-susceptible S. aureus) and one patient with frontal sinusitis (P. aeruginosa isolated at study enrolment).
One patient with pansinusitis and a negative microbiological diagnosis at study enrolment had a superinfection with H. influenzae (a non-β-lactamase-producing 
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strain; moxifloxacin MIC = 0.062 mg/l) at the post-treatment visit (V3).
ANALYSIS OF FAILURES OBSERVED IN THE PP POPULATION
Clinical failure at V3 was observed in 16 patients in the PP population (7.4%) ( Table  5) , including nine patients diagnosed with maxillary sinusitis after failure of first-line antimicrobial therapy, and seven with sinusitis and high risk of complications. Six of these failures were reported at V2. In general, the characteristics of patients with clinical failure did not differ from those of other patients. Bacteriological documentation at study enrolment was available for seven of these patients, and was accompanied by bacteriological eradication in four cases (non-β-lactamase-producing H. influenzae [n = 2], S. pneumoniae [n = 2]). In the remaining three patients, the bacteriological response was defined as 'assumed persistence' due to the absence of control swabs at study enrolment.
SAFETY
Safety analysis was performed in 255 patients (ITT population). Thirty-one patients (12.2%) experienced a total of 45 adverse events classified by the investigators as possibly or probably related to the study medication (summarized in Table 6 ). Events were reported if they occurred on at least two occasions.
Discussion
Fluoroquinolones are active against pneumococcus and are an efficacious treatment for acute sinusitis, including maxillary sinusitis. 14 -17 The Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) recommends that, due to the availability of therapeutic alternatives, fluoroquinolones should not be used as firstline treatment for maxillary sinusitis. They should be reserved for use in severe clinical situations, infection sites with a high risk of complications, and/or infection sites untested in clinical trials. Our study constitutes the first published clinical data in support of the AFSSAPS recommendations. 13 Our objective was to confirm the AFSSAPS recommendations by evaluating the clinical and bacteriological efficacy of moxifloxacin, administered in doses approved by the AMM -one 400 mg tablet once daily for 7 days -for acute sinusitis. Inclusion of patients with failures to various first-line antimicrobials impacted the study design, especially the decision to conduct a non-comparative study.
Re-review of all radiographs by the study co-ordinator prior to efficacy analysis confirmed the diagnosis of sinusitis and its specific location. Direct examination of bacteriological samples and quantitative culture supported the diagnosis of bacterial sinusitis by eliminating strains of normal colonizing flora from the analysis. 18, 19 This study also provides information about firstline prescribing for acute maxillary sinusitis. In accordance with current recommendations, 13 amoxicillin clavulanate (2 -3 g/day), second generation oral cephalosporins (cefuroxime axetil), third generation oral cephalosporins (cefotiam hexetil and Visual abnormalities 2 (0.8) *Only events that occurred ≥ 2 times are reported. † Incidence, ratio of the number of patients with adverse events to the number of patients valid for safety analysis. Moxifloxacin and acute maxillary sinusitis cefpodoxime proxetil) and pristinamycin were among the most commonly used medications. Macrolides were also used as first-line therapy in many cases, even though they should not be considered as effective treatment for acute sinusitis due to their inconsistent activity against pneumococcus and H. influenzae. The mean duration of prior treatment (7.2 days) confirmed the treatment-failure status of patients at study enrolment. The bacterial aetiology of maxillary sinusitis after first-line treatment failure (group 1) and sinusitis with high risk of complications (group 2) presented only a slightly different profile from that observed in untreated sinusitis, although the isolation rate of Enterobacteriaceae was slightly higher. 20 -22 One of the differences, which has therapeutic consequences, is the higher incidence of isolated PSAP strains and β-lactamase-producing H. influenzae strains in the study. This confirms the importance of new fluoroquinolones in this clinical setting. It should be noted that in this study, isolation of these strains was higher in patients with first-line treatment failures than those with sinusitis and risk of complications who did not usually receive prior antibiotics. Similarly, the rates of resistant strains in our study are higher than rates reported in the literature for untreated maxillary sinusitis. Our clinical and bacteriological success rates confirm the efficacy of moxifloxacin in patients with sinusitis following first-line treatment failure. These results may be explained by bacteriological aetiologies and the pharmacokinetic and pharmacodynamic characteristics of moxifloxacin. The concentration of moxifloxacin in sinus mucosa membranes is 2 -3 times higher than plasma concentrations. 23 These concentrations were assessed in patients whose local conditions -subacute sinusal foci, i.e., relatively mild inflammation -were comparable to those of patients included in our study. These local conditions have been demonstrated to have a significant impact on antibiotic diffusion 24 and might explain the improved sinus tissue penetration of fluoroquinolones, especially compared with β-lactams. Pharmacodynamic values for the inhibition ratio (C max /MIC 90 ) and the area under the inhibitory curve (ASC 24 / MIC 90 )predictive parameters of clinical response for concentration-dependent antibiotics such as fluoroquinolones -are remarkably high for moxifloxacin, especially against pneumococcus, including strains of varying susceptibility to penicillin. 25 Currently, three sources of information on the safety of moxifloxacin are available: studies associated with clinical development; post-marketing surveillance studies; and reports collected in countries where it is being marketed. The safety of moxifloxacin in specific body systems, such as the cardiovascular system, has also been monitored and analysed. Evaluation of the post-marketing experience of > 10.5 million patients treated with moxifloxacin 26 confirms its safety profile compared with other antibiotics prescribed for the same indications. In this post-marketing study, the incidence and profile of adverse events were similar to those reported in the literature when the antibiotic was administered per the study protocol. 14, 15 Generally, administration of moxifloxacin according to AMM guidelines provides a favourable benefit/risk ratio for second-line treatment of maxillary sinusitis or as first-line therapy of sinusitis with a high risk of complications.
To conclude, the results of this study demonstrate that oral administration of 400 mg/day moxifloxacin for 7 days is an effective and well tolerated treatment for acute maxillary sinusitis after first-line P Gehanno, P Berche, A Perrin Moxifloxacin and acute maxillary sinusitis antimicrobial treatment failure, frontal and sphenoidal sinusitis, and pansinusitis. These results confirm the AFSSAPS recommendations regarding the increasingly important role of fluoroquinolones for treating diseases involving pneumococcus. 13 
